Summary
Updated Aug 31, 2026
Scott A. Gangloff is Chief Technology Officer of Akero Therapeutics, Inc. (AKRO). 4 SEC Form 4 filings on record going back to 2024, most recently on 9 December 2025.
Recent Transactions
5Every recent SEC Form 4 transaction Scott A. Gangloff has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Scott A. Gangloff files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Andrew Cheng - $2.99M of AKRO open-market activity in the last 12 months
- Jonathan Young - $1.20M of AKRO open-market activity in the last 12 months
- Timothy Rolph - $1.15M of AKRO open-market activity in the last 12 months
- William Richard White - $28K of AKRO open-market activity in the last 12 months
- Catriona Yale - $28K of AKRO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Scott A. Gangloff?
Scott A. Gangloff is a corporate insider, tracked as Chief Technology Officer of Akero Therapeutics, Inc. (AKRO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Scott A. Gangloff last file a Form 4?
The most recent primary Form 4 on record is dated 9 December 2025, one of 4 filings going back to 2024.
Where can I see all of Scott A. Gangloff's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Scott A. Gangloff and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
